BCL2L11 and chronic myelogenous leukemia, BCR-ABL1 positive: This leads us to consider that some CML patients could have a genomic predisposition to poorly respond to treatment and thus could benefit from a personalized biological monitoring and treatment adaptation particularly associating BH3 mimetics to TKI as previously suggested [8], [29] for compensating the Bim deficiency.